# Sound Bioventures

> Sound Bioventures is a life-sciences venture investor. It co-led Altay Therapeutics' $37 million Series A, announced closed on October 14, 2026, to advance its investigational oral DUX4 inhibitor for FSHD. Sound's individual check size was not disclosed.

## Profile

- **Stage-based planning range:** $1M–$10M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** N/A
- **AUM:** N/A
- **Rounds they lead:** Series A
- **Rounds they invest:** N/A
- **Last verified:** 2026-10-15T07:20:00Z

## Links

- [Website](https://soundbioventures.com/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/sound-bioventures